Recommendations for the use of biologic therapy from the Italian Society for Rheumatology

off-label use.

Monica Todoerti, Nicolo' Pipitone, Marco Matucci-Cerinic, Carlomaurizio Montecucco, Roberto Caporali, Society for Rheumatology Italian Society for Rheumatology

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The advent of biological agents has provided further opportunities to treat resistant or relapsing rheumatic diseases, with robust data for rheumatoid arthritis and spondyloarthritis coming from randomised controlled trials. However there are data also on other rare inflammatory rheumatic diseases even if the evidence available may be heterogeneous and/or controversial. Another challenging scenario is represented by diseases that are not uncommon, but that may present with multiple manifestations and prove resistant to conventional therapies, thus requiring the use of biological agents. To assist physicians in making correct therapeutic choices in such cases, the Italian Society for Rheumatology (SIR) has developed specific recommendations for the use of biological agents in rare disease or for the off-label use of such agents in refractory inflammatory disorders.

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume29
Issue number3 Suppl 66
Publication statusPublished - May 2011

Fingerprint

Off-Label Use
Biological Therapy
Biological Factors
Rheumatology
Rheumatic Diseases
Rare Diseases
Rheumatoid Arthritis
Randomized Controlled Trials
Physicians
Therapeutics

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Todoerti, M., Pipitone, N., Matucci-Cerinic, M., Montecucco, C., Caporali, R., & Italian Society for Rheumatology, S. F. R. (2011). Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label use. Clinical and Experimental Rheumatology, 29(3 Suppl 66).

Recommendations for the use of biologic therapy from the Italian Society for Rheumatology : off-label use. / Todoerti, Monica; Pipitone, Nicolo'; Matucci-Cerinic, Marco; Montecucco, Carlomaurizio; Caporali, Roberto; Italian Society for Rheumatology, Society for Rheumatology.

In: Clinical and Experimental Rheumatology, Vol. 29, No. 3 Suppl 66, 05.2011.

Research output: Contribution to journalArticle

Todoerti, M, Pipitone, N, Matucci-Cerinic, M, Montecucco, C, Caporali, R & Italian Society for Rheumatology, SFR 2011, 'Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label use.', Clinical and Experimental Rheumatology, vol. 29, no. 3 Suppl 66.
Todoerti, Monica ; Pipitone, Nicolo' ; Matucci-Cerinic, Marco ; Montecucco, Carlomaurizio ; Caporali, Roberto ; Italian Society for Rheumatology, Society for Rheumatology. / Recommendations for the use of biologic therapy from the Italian Society for Rheumatology : off-label use. In: Clinical and Experimental Rheumatology. 2011 ; Vol. 29, No. 3 Suppl 66.
@article{10a4d90e9f8042ba9e41a9476e898a4b,
title = "Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label use.",
abstract = "The advent of biological agents has provided further opportunities to treat resistant or relapsing rheumatic diseases, with robust data for rheumatoid arthritis and spondyloarthritis coming from randomised controlled trials. However there are data also on other rare inflammatory rheumatic diseases even if the evidence available may be heterogeneous and/or controversial. Another challenging scenario is represented by diseases that are not uncommon, but that may present with multiple manifestations and prove resistant to conventional therapies, thus requiring the use of biological agents. To assist physicians in making correct therapeutic choices in such cases, the Italian Society for Rheumatology (SIR) has developed specific recommendations for the use of biological agents in rare disease or for the off-label use of such agents in refractory inflammatory disorders.",
author = "Monica Todoerti and Nicolo' Pipitone and Marco Matucci-Cerinic and Carlomaurizio Montecucco and Roberto Caporali and {Italian Society for Rheumatology}, {Society for Rheumatology}",
year = "2011",
month = "5",
language = "English",
volume = "29",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3 Suppl 66",

}

TY - JOUR

T1 - Recommendations for the use of biologic therapy from the Italian Society for Rheumatology

T2 - off-label use.

AU - Todoerti, Monica

AU - Pipitone, Nicolo'

AU - Matucci-Cerinic, Marco

AU - Montecucco, Carlomaurizio

AU - Caporali, Roberto

AU - Italian Society for Rheumatology, Society for Rheumatology

PY - 2011/5

Y1 - 2011/5

N2 - The advent of biological agents has provided further opportunities to treat resistant or relapsing rheumatic diseases, with robust data for rheumatoid arthritis and spondyloarthritis coming from randomised controlled trials. However there are data also on other rare inflammatory rheumatic diseases even if the evidence available may be heterogeneous and/or controversial. Another challenging scenario is represented by diseases that are not uncommon, but that may present with multiple manifestations and prove resistant to conventional therapies, thus requiring the use of biological agents. To assist physicians in making correct therapeutic choices in such cases, the Italian Society for Rheumatology (SIR) has developed specific recommendations for the use of biological agents in rare disease or for the off-label use of such agents in refractory inflammatory disorders.

AB - The advent of biological agents has provided further opportunities to treat resistant or relapsing rheumatic diseases, with robust data for rheumatoid arthritis and spondyloarthritis coming from randomised controlled trials. However there are data also on other rare inflammatory rheumatic diseases even if the evidence available may be heterogeneous and/or controversial. Another challenging scenario is represented by diseases that are not uncommon, but that may present with multiple manifestations and prove resistant to conventional therapies, thus requiring the use of biological agents. To assist physicians in making correct therapeutic choices in such cases, the Italian Society for Rheumatology (SIR) has developed specific recommendations for the use of biological agents in rare disease or for the off-label use of such agents in refractory inflammatory disorders.

UR - http://www.scopus.com/inward/record.url?scp=80055095241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055095241&partnerID=8YFLogxK

M3 - Article

VL - 29

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3 Suppl 66

ER -